"The US Food and Drug Administration (FDA) has approved diclofenac sodium injection (Dyloject, Hospira Inc), a proprietary nonsteroidal anti-inflammatory drug (NSAID) for the treatment of mild to moderate pain, and for the management of mod"...
Ethrane Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Ethrane (enflurane) Liquid For Inhalation is a general inhalation anesthetic drug used for induction and maintenance of general anesthesia. This medication is available in generic form. Common side effects include elevated body temperature, seizures, low blood pressure, slow or shallow breathing, low blood oxygen, arrhythmias, shivering, nausea, vomiting, or liver damage.
Ethrane is delivered from a vaporizer during anesthesia, and the dose is individualized for each patient. Ethrane may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Ethrane should be used only if prescribed. Tell your doctor if you are pregnant. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Ethrane (enflurane) Liquid For Inhalation Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Ethrane FDA Prescribing Information: Side Effects
- Malignant hyperthermia (see WARNINGS).
- Motor activity exemplified by movements of various muscle groups and/or seizures may be encountered with deep levels of ETHRANE (enflurane, USP) anesthesia, or light levels with hypocapnia.
- Hypotension, respiratory depression, and hypoxia have been reported.
- Arrhythmias, shivering, nausea and vomiting have been reported.
- Elevation of the white blood count has been observed.
- Mild, moderate and severe liver injury, including hepatic failure, may rarely follow anesthesia with enflurane. Serum transaminases may be increased and histologic evidence of injury may be found. The histologic changes are neither unique nor consistent. In several of these cases, it has not been possible to exclude enflurane as the cause or as a contributing cause to liver injury. The incidence of unexplained hepatotoxicity following the administration of enflurane is unknown, but it appears to be rare and not dose related.
ETHRANE (enflurane, USP) has also been associated with perioperative hyperkalemia (see WARNINGS).
The following adverse events have been identified during post-approval use of ETHRANE (enflurane, USP). Due to the spontaneous nature of these reports, the actual incidence and relationship of ETHRANE (enflurane, USP) to these events cannot be established with certainty.
Cardiac Disorders: Cardiac arrest
Hepatobiliary Disorders: Hepatic necrosis, Hepatic failure
Read the entire FDA prescribing information for Ethrane (Enflurane)
Additional Ethrane Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Chronic Pain/Back Pain
Find tips and advances in treatment.